Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Two huge licensing deals help Oxford BioMedica swing to a first-half profit

Oxford signed deals with Bioverativ and Axovant, which could be worth upwards of US$1bn over the next few years
scientist in lab
Oxford also has an ongoing deal with Novartis, potentially worth more than US$100mln

Two huge licensing deals helped gross income at Oxford Biomedica PLC (LON:OXB) to more than double in the first half of the year.

Earlier this year, Oxford signed an exclusive licensing deal worth up to US$842.5mln with Axovant Sciences for its OXB-102 Parkinson’s disease treatment.

READ: Oxford BioMedica signs potentially lucrative deal with Axovant

It also inked a US$105mln collaboration and licence deal with Bioverativ – now part of Sanofi – in February, giving the latter access to its LentiVector platform.

Oxford received just shy of £20mln in upfront payments for those two deals in the opening six months of 2018, leading to gross income more than doubling to £36.0mln (H1 17: £16.5mln).

Those receipts also meant the company swung to an operational profit of £9.4mln, compared with a loss of £2.2mln a year earlier.

Oxford’s cash position was also strengthened, rising to £44.0mln at the end of June (H1 17: £10.2mln).

On top of this, the firm’s collaboration with Swiss pharma giant Novartis is also “progressing well”.

Last summer, Oxford signed a major contract with Novartis to supply antiviral lectors used in the latter’s cell therapy treatment for leukaemia.

That deal could bring in more than US$100mln over the three-year term, and Novartis received some good news in the first half when Kymriah was approved by the US FDA, while the NHS announced the treatment will be made available to children and young adults in England.

Transformative year, says CEO

Oxford Biomedica has had a transformative year so far,” said chief executive John Dawson.

“The company's significant progress is highlighted by the ongoing success of our collaboration with Novartis for Kymriah, as well as a number of new partnership agreements.

“Specifically, the exclusive worldwide licence agreement signed with Axovant for OXB-102 successfully executes on our pre-stated strategy to externalise product development beyond the end of the pre-clinical phase.

“Following these developments, we are greatly encouraged by the outlook for the full year and with the finances now in place, we are able to accelerate our capacity expansion plans to meet future demand.”

Shares rose 5.4% to 857.5p, more than double what they were worth this time last year.

View full OXB profile View Profile

Oxford Biomedica Timeline

Related Articles

June 20 2018
“FLU-v is designed to protect against a broad range of influenza viral strains and this includes unexpected seasonal strains or a potentially devastating pandemic strain"
tumour cells
July 25 2018
Sign-off by the US Food & Drug Administration is considered the "global standard for approval", the company said
consumer health segment overview
The company sells clinically validated anti-ageing products for hair, skin and body.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use